STOCK TITAN

Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Verrica Pharmaceuticals Inc. will provide a corporate update and report its first-quarter 2024 financial results on May 13, 2024. The company, focused on dermatology therapeutics, will host a conference call and live webcast to discuss its financial performance and future prospects. Investors can participate via telephone or webcast to learn about Verrica's progress and financial status.

Positive
  • None.
Negative
  • None.

WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024.

Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13746100. Participants are asked to dial in 10 minutes before the start of the call to register.

A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, Verrica’s lead product, YCANTH™ (cantharidin), became the first treatment approved by the FDA to treat pediatric and adult patients with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. VP-102 is also in development to treat common warts and external genital warts, two of the largest unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for dermatologic oncology conditions. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

Terry Kohler 
Chief Financial Officer 
tkohler@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

Chris Calabrese 
LifeSci Advisors 
ccalabrese@lifesciadvisors.com


FAQ

When will Verrica Pharmaceuticals provide a corporate update and report first-quarter financial results for 2024?

Verrica Pharmaceuticals will provide a corporate update and report first-quarter financial results for 2024 on May 13, 2024.

What does Verrica Pharmaceuticals focus on as a company?

Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions.

How can individuals participate in the live call for the corporate update?

Individuals can participate in the live call for the corporate update by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) using the conference ID: 13746100.

Where can a replay of the webcast be accessed?

A replay of the webcast can be accessed on Verrica's website for 90 days following the event.

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

VRCA Rankings

VRCA Latest News

VRCA Stock Data

56.32M
42.67M
34.54%
43.79%
8.69%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WEST CHESTER